MedWatch

Bank analyst on Novo Nordisk report: Impressive quarter, to say the least

Novo Nordisk has beaten expectations in terms of both its GLP drugs and its obesity treatment, and according to senior equity analyst at Sydbank Søren Løntoft Hansen, the report which Denmark's largest pharmaceutical company sent out Wednesday afternoon is highly impressive.

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

The Q2 report that Novo Nordisk introduced on Wednesday afternoon is impressive, to say the least.

This is according to Søren Løntoft Hansen, who is senior equity analyst at the Danish bank Sydbank.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs